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Coronavirus E protein is a small membrane protein found in the virus
envelope. Different coronavirus E proteins share striking biochemical and
functional similarities, but sequence conservation is limited. In this report,
we studied the E protein topology from the new SARS-CoV-2 virus both
in microsomal membranes and in mammalian cells. Experimental data
reveal that E protein is a single-spanning membrane protein with the
N-terminus being translocated across the membrane, while the C-terminus
is exposed to the cytoplasmic side (Ntlum/Ctcyt). The defined membrane
protein topology of SARS-CoV-2 E protein may provide a useful framework
to understand its interaction with other viral and host components and
contribute to establish the basis to tackle the pathogenesis of SARS-CoV-2.1. Introduction
Coronavirus disease 2019 (COVID-19), an extremely infectious human disease
caused by coronavirus SARS-CoV-2, has spread around the world at an unprece-
dented rate, causing aworldwide pandemic.While the numberof confirmed cases
continues to grow rapidly, the molecular mechanisms behind the biogenesis of
viral proteins are not fully unravelled. The SARS-CoV-2 genome encodes up to
29 proteins, although somemay not get expressed [1]. The viral RNA is packaged
by the structural proteins to assemble viral particles at the ERGIC (ER-Golgi inter-
mediate compartment). The fourmajor structural proteins are the spike (S) surface
glycoprotein, themembrane (M)matrix protein, the nucleocapsid (N) protein, and
the envelope (E) protein. These conserved structural proteins are synthesized from
sub-genomic RNAs (sgRNA) encoded close to the 30 end of the viral genome [2].
Among the four major structural proteins, the E protein is the smallest and has
the lowest copy number of the membrane proteins found in the lipid envelope of
mature virus particles (reviewed [3,4]). However, it is critical for pathogenesis of
other human coronaviruses [5,6]. Interestingly, the sgRNA encoding E protein is
one of the most abundantly expressed transcripts despite the protein having a
low copy number in mature viruses [1]. It encodes a 75 residues long polypeptide
with a predicted molecular weight of approximately 8 kDa. Two aliphatic amino
acids (Leu and Val) constitute a substantial portion (36%, 27/75) of the E protein,
which accounts for the high grand average of hydropathicity (GRAVY) index of the
protein (1.128), as calculated using the ExPASy ProtParam tool (https://web.
expasy.org/protparam/). Comparative sequence analysis of the E protein of
SARS-CoV-2 and the other six known human coronaviruses do not reveal any
large homologous/identical regions (figure 1), with only the initial methionine,
Leu39, Cys40 and Pro54 being ubiquitously conserved. With regard to overall
sequence similarity SARS-CoV-2 E protein has the highest similarity to SARS-
CoV (94.74%) with only minor differences (figure 1b), followed by MERS-CoV
(36.00%). Interestingly, sequence similarities are significantly lower for the
other four human coronaviruses, which usually cause mild to moderate






































Figure 1. (a) Multi-alignment of amino acid sequences of the E protein of SARS-CoV-2 and the other six human coronavirus. SARS-CoV severe acute respiratory
syndrome coronavirus (UniProt P59637), MERS-CoV Middle East respiratory syndrome coronavirus (UniProt K9N5R3), HCoV-HKU1 (UniProt Q0ZJ83), HCoC-OC43 (Uni-
Prot Q4VID3), HCoC-229E (UniProt P19741) and HCoV-NL63 (UniProt Q5SBN7). Predicted TM segments at UniProt are highlighted in a grey box. Native predicted
glycosylation acceptor sites in SARS-CoV-2 are shown in bold and charged residues highlighted with + or – symbols on top. Conserved residues are shown in
orange. Differences between SARS-CoV-2 and SARS-CoV are highlighted as yellow boxes. (b) Phylogenetic data and (c) tree obtained with Clustal Omega





upper-respiratory tract illness typical for common cold,with the
lowest similarity found for HCOV-NL63 (18.46%). These find-
ings are consistent with the phylogenetic tree proposed based
on the amino acid sequences of the human coronavirus E
proteins using ClustalW (figure 1c).2. Results and discussion
2.1. E protein topology prediction
Computer-assisted analysis of the SARS-CoV-2 E protein amino
acid sequence using seven popular predictionmethods showed
that all membrane protein prediction algorithms except
MEMSAT-SVM suggested the presence of one transmembrane
(TM) segment located roughly around amino acids 12 to 39
(table 1), which is not predicted as a cleavable signal sequence
according to SignalP-5.0 [7]. Regarding E protein topology,
TMHMM and Phobius predicted an N-terminus cytosolic
orientation, while MEMSAT-SVM, TMpred, HMMTop and
TOPCONS predicted an N-terminus luminal orientation.
Thesediscrepancies foundamong thepredictions fromdifferent
algorithms motivated experimental approaches.
2.2. Insertion into microsomal membranes
First, we performed in vitro E protein transcription/translation
experiments in the presence of ER-derived microsomes and
[35S]-labelled amino acids. Themembrane insertion orientation
of the predicted TM segment into microsomal membranes was
based on N-linked glycosylation and summarized in figure 2a.
N-linked glycosylation has been extensively used as topologi-
cal reporter for more than two decades [8]. In eukaryotic
cells, proteins can only be glycosylated in the lumen of the
ER because the active site of oligosaccharyl transferase (OST),
a translocon-associated protein responsible forN-glycosylation[9], is located there [10]; no N-linked glycosylation occurs
within the membrane or in the cytosol. It is important to note
that two possible N-linked glycosylation sites are located
C-terminally of the predicted TM segment in E protein wild-
type sequence at positions N48 and N66 (figure 1). However,
N48 is not expected to be modified even if situated lumenally
due to the close proximity of this glycosylation acceptor site
to the membrane if the hydrophobic region is recognized as
TM by the translocon [11,12]. Thus, mono-glycosylation (at
N66) would serve as a C-terminal translocation reporter. To
test N-terminal translocation, a construct was engineered
where a predicted highly efficient glycosylation acceptor site
(i.e. Asn-Ser-Thr, NST) was designed at the N-terminus.
When E protein constructs were translated in vitro in the
presence of microsomes, the protein was significantly glycosy-
lated when the N-terminal designed glycosylation site was
present, as shown by the increase in the electrophoretic mobi-
lity of the slower radioactive band after an endoglycosidase
H (Endo H) treatment (figure 2b, lanes 1 and 2). However,
when a control (Gln-Ser-Thr, QST) that is not a glycosylation
acceptor site (lane 3) or the wild-type (lane 4) sequences were
translated, E protein molecules were minimally glycosylated.
Since multiple topologies have been reported for previous cor-
onavirus E proteins [13–17], SARS-CoV-2 E protein insertion
into the microsomal membranes in two opposite orientations
cannot be discounted, but according to our data being
dominant an Ntlum/Ctcyt orientation.2.3. E protein integrates cotranslationally into
microsomal membranes
We have previously reported that several viral membrane
proteins are cotranslationally inserted into ER-derived micro-
somal membranes [18–20]. Since membrane protein insertion




























Figure 2. Translocon-mediated insertion of E protein variants into micro-
somal membranes. (a) Schematic representation of E protein constructs.
Glycosylation acceptor Asn residues are indicated. (b) In vitro translation in
the presence of microsomes of the different E protein constructs. Construct
containing inserted asparagine and threonine residues at positions 3 and 5
(NST; lanes 1–2) or glutamine and threonine at positions 3 and 5 (lane
3), and wild-type variants (lane 4) were translated in the presence of micro-
somes. NST variant was split and half of the sample was Endo H treated (lane
1). Bands of non-glycosylated and glycosylated proteins are indicated by
white and black dots, respectively. (c) E protein (harbouring an engineered
glycosylation site at the N-terminus, positions 3–5) was translated in
either the absence (lanes 1 and 2) or the presence (lanes 3 and 4) of micro-
somal membranes. In lanes 1 and 2, microsomal membranes were added
posttranslationally (after 1 h, post-) and incubation was continued for another
1 h. Samples in lanes 1 and 3 were treated later with EndoH. The gels are
representative of at least three independent experiments.
Table 1. Computer analysis of the SARS-CoV-2 E protein amino acid
sequence topology. n.p., non-predicted.
algorithm Nt Ct TMDs (start-end)
ΔG predictor n.p. n.p. 1 (17–39)
TMHMM cytosol lumen 1 (12–34)
MEMSAT-SVM lumen lumen 2 (10–39) (43–58)
TMpred lumen cytosol 1 (17–34)
HMMTop lumen cytosol 1 (11–35)
Phobius cytosol lumen 1 (12–37)






























Figure 3. E protein topology in mammalian cells. To determine the topology
in vivo HEK-293T cells were transfected with C-terminal tagged (c-myc) E
protein variants. (a) Constructs encoding wild-type (Wt; lanes 1 and 2),
inserted asparagine and threonine at positions 3 and 5 (NST; lanes 3 and
4) or glutamine and threonine at positions 3 and 5 (QST; lanes 5 and 6)
were Endo H (+) or mock (−) treated. Filled and empty Y-shaped symbols
denoted acceptor (NST) and non-acceptor (QST) glycosylation sites, respect-
ively. (b) Additionally, we included constructs containing similar Wt (lanes
1 and 2), replaced glutamic acids at positions 7 and 8 by lysine residues
(EE > KK; lanes 3 and 4) or NST (lanes 5 and 6) variants with an extra gly-
cosylation site inserted at the Ct end of the protein. Once again, to confirm
the glycosylated nature of the higher molecular weight bands, samples were
either Endo H (+) or mock (−) treated. Designed glycosylation sites and tags





formation of a ribosome, the translocon and the OST [10], we
sought to investigate whether or not SARS-CoV-2 E protein is
cotranslationally inserted into the ER membrane by blocking
protein synthesis after E protein (harbouring N-terminal NSTglycosylation site) has been translated in the absence of mem-
branes. As shown in figure 2c, E protein (NST) was efficiently
glycosylated when microsomal membranes were added to
the translation mixture cotranslationally (lane 4). But when
microsomal membranes were included posttranslationally
after the translation was inhibited by cycloheximide, the
protein was only residually glycosylated (lane 2), suggesting
that E protein is mainly integrated cotranslationally through
the ER translocon. This means that the microsomal insertion
machinery recognizes, orients and provides a path into the
membrane for this viral protein.2.4. Membrane topology in mammalian cells
To analyse protein topology in mammalian cells, a series of E




4were transfected into HEK-293T cells. As shown in figure 3a,
only an E protein construct harbouring the N-terminal
engineered acceptor site was efficiently modified (lanes
1–4), denoting an N-terminal ER luminal localization
(Ntlum). Several topological parameters have been proposed
to govern membrane protein topology, among which the pre-
ferential distribution of positively charged residues in the
cytosol (positive-inside rule) has been established as the pri-
mary topology determinant both experimentally [21] and
statistically [22]. E protein is a single-spanning membrane
protein with an even net charge distribution on both sides
of the membrane. There are only eight charged residues
along the protein sequence (two negatively charged residues
preceding the TM segment, and five positively and one nega-
tively charged residues at the C-terminal domain; figure 1a),
which correlates well the observed topology with the
‘positive-inside rule’. However, negatively charged residues
have also been proved to significantly affect the topology
[23]. To test the robustness of the observed topology, we
added an optimized Ct glycosylation tag [24] and replaced
the two negatively charged residues located in the translocated
N-terminal domain (E7 and E8) by two lysine residues
(figure 3b). In cells expressing this mutant E protein (EE >
KK), the protein retained its C-terminal tail at the cytosolic
side of the membrane as indicated by the absence of glycosy-
lated forms (figure 3b, lanes 3 and 4). These data reveal that
topological determinants have only a minor effect on viral
membrane protein topology as previously demonstrated for
other viruses [25] and suggest that viralmembrane protein top-
ology could have co-evolved with the protein environment of
its natural host, ensuring proper membrane protein orien-
tation. Altogether, the present in vivo results demonstrate
that SARS-CoV-2 E protein is a single-spanning membrane
protein with an Ntlum/Ctcyt orientation in mammalian cell
membranes. Similarly, SARS-CoV E protein was shown to
mainly adopt an Ntlum/Ctcyt topology in the infected cell
and mammalian cells expressing the recombinant protein
[26]. This topology is compatible with the ion channel capacity
described previously [27], andwith the recently published pen-
tameric structural model of SARS-CoV E protein in micelles
[28], in which the C-terminal tail of the protein is α-helical
and extramembrane.3. Concluding remarks
Themembrane topology described herewould allow the cyto-
plasmic C-terminal tail of the E protein to interact with the
C-termini of M and/or S SARS-CoV-2 membrane-embedded
proteins [3], and/or with Golgi scaffold proteins as previously
described for other coronaviruses [29], to induce virus bud-
ding or influence vesicular traffic through the Golgi complex
by collecting viral membrane proteins for assembly at Golgi
membranes. Future experiments will have to unravel whether
these functions involve the SARS-CoV-2 E protein.4. Material and methods
4.1. Enzymes and chemicals
TNTT7Quick for PCRDNAwas fromPromega (Madison,WI,
USA). Dog pancreas ER rough microsomes were from tRNA
Probes (College Station, TX, USA). EasyTag EXPRESS35SProtein Labeling Mix, [35S]-L-methionine and [35S]-L-cysteine,
for in vitro labelling was purchased from Perkin Elmer
(Waltham, MA, USA). Restriction enzymes were from New
England Biolabs (Massachusetts, USA) and endoglycosidaseH
was from Roche Molecular Biochemicals (Basel, Switzerland).
PCR and plasmid purification kits were from Thermo
Fisher Scientific (Ulm, Germany). All oligonucleotides were
purchased from Macrogen (Seoul, South Korea).4.2. Computer-assisted analysis of E protein sequence
Prediction of transmembrane segments was done using up to
7 of the most common methods available on the Internet: ΔG
Predictor [30,31] (http://dgpred.cbr.su.se/), TMHMM [32]
(http://www.cbs.dtu.dk/services/TMHMM/), MEMSAT-
SVM [33] (http://bioinf.cs.ucl.ac.uk/psipred/), TMpred
(https://embnet.vital-it.ch/software/TMPRED_form.html),
HMMTop [34] (http://www.enzim.hu/hmmtop/), Phobius
[35] (http://phobius.sbc.su.se/) and TOPCONS [36] (http://
topcons.net/). All user-adjustable parameters were left at
their default values.4.3. DNA manipulation
Full-length E protein was synthesized by Invitrogen (GeneArt
gene synthesis) and subcloned into KpnI linearized pCAGGS
in-house version [37] using In-Fusion HD cloning Kit
(Takara) according to the manufacturer’s instructions. For
in vitro assays, DNA was amplified by PCR adding the T7
promoter and the relevant glycosylation sites during the pro-
cess. N-terminal NST glycosylation site was designed by
inserting an asparagine and a threonine before and after
Ser3, respectively. Control no-glycosylable QST site was
introduced in similarly inserting a glutamine residue instead
of an asparagine. All E protein variants were obtained by
site-directed mutagenesis using QuikChange kit (Stratagene,
La Jolla, California) and were confirmed by sequencing the
plasmid DNA at Macrogen Company (Seoul, South Korea).4.4. Translocon-mediated insertion into microsomal
membranes
E protein variants, PCR amplified from pCAGGS, were tran-
scribed and translated using the TNT T7 Quick for PCR DNA
coupled transcription/translation system (Promega, USA).
The reactions contained 10 µl of TNT, 2 µl of PCR product,
1 µl of EasyTag (5 µCi) and 0.6 µl of column-washed
microsomes (tRNA Probes, USA) and were incubated for
60 min at 30°C. Translation products were ultracentrifuged
(100 000g for 15 min) on a 0.5 M sucrose cushion and ana-
lysed by SDS-PAGE. For the endoglycosidase H (Endo H),
the treatment was done as previously described [20]. Briefly,
the translation mixture was diluted in 120 µl of PBS and cen-
trifuged on a 0.5 M sucrose cushion (100 000g 15 min 4°C).
The pellet was then suspended in 50 µl of sodium citrate
buffer with 0.5% SDS and 1% β-mercaptoethanol, boiled
5 min, and incubated 1 h at 37°C with 1 unit of Endo
H. Then, the samples were analysed by SDS-PAGE and gels
were visualized on a Fuji FLA3000 phosphorimager using




54.5. Postranslational and cotranslational insertion assay
E protein DNAs were transcribed/translated (30°C 1 h) either
in the absence (figure 2c, post- samples) or in the presence
(co- samples) of microsomal membranes. The translation was
inhibited with cycloheximide (10 min, 26°C, 2 mg ml−1 final
concentration), after which microsomes were added to those
samples labelled as posttranslational and incubated for an
additional hour at 30°C. Subsequently, membranes were col-
lected by ultracentrifugation; half of the samples were
EndoH treated and analysed by SDS-PAGE (double volume
was loaded for the post-samples due to the lower translation
levels observed). Protein molecules were visualized on a Fuji
FLA3000 phosphorimager.
4.6. E protein expression in mammalian cells
E protein sequence variants were tagged with a c-myc epitope
at their C-terminus (Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-
Leu, EQKLISEEDL) and inserted in a pCAGGS-ampicillin plas-
mid. When appropriate (figure 3b), an optimized glycosylation
site followed by a flexible dipeptide (Asn-Ser-Thr-Gly-Ser,
NSTGS) [24,38] preceded the c-myc epitope. Once the sequence
was verified, plasmids were transfected into HEK293-T cells
using Lipofectamine 2000 (Life Technologies) according to the
manufacturer’s protocol. Approximately 24 h post-transfection
cells were harvested and washed with PBS buffer. After short
centrifugation (1000 r.p.m. for 5 min on a table-top centrifuge),
cells were lysed by adding 100 µl of lysis buffer (30 mM
Tris-HCl, 150 mM NaCl, 0.5% Nonidet P-40), sonicated in anice bath in a bioruptor (Diagenode) during 10 min and were
centrifugated. Total protein was quantified and equal amounts
of protein submitted to Endo H treatment or mock-treated,
followed by SDS-PAGE analysis and transferred into a PVDF
transfer membrane (ThermoFisher Scientific). Protein glyco-
sylation status was analysed by Western Blot using an anti-
c-myc antibody (Sigma), anti-rabbit IgG-peroxidase conjugated
(Sigma) and with ECL developing reagent (GE Healthcare).
Chemiluminescence was visualized using an ImageQuantTM
LAS 4000mini Biomolecular Imager (GE Healthcare).Data accessibility. This article does not contain any additional data.
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